**Product Name:** DABRA Laser System / Pharos RA-308 Excimer Laser

*Lower Limb Advanced Arterial Therapeutics, Lower Limb Chronic Total Occlusions - CTO, Medtronic PV Lower Limb Advanced Arterial Therapeutics, Peripheral Vascular Therapeutics - In Development*

**Description:**
The DABRA system utilizes a fiber-optic like device which removes total blockages within arteries using a minimally invasive and simple procedure (endovascularly), based on the proven Pharos RA-308 excimer laser system which is a high powered and versatile excimer laser for clinical dermatology including psoriasis, vitiligo, atopic dermatitis, and leukoderma.

**Company/Sponsor:**
- Ra Medical Systems, Inc.

**Vessels:**
- Lower Limb Arteries

**General Modality:**
- Medical Devices

**Specific Modality:**
- Other Medical Devices / Systems

**General Product Type:**
- Excimer Laser Ablation Catheter

**Clinical Trials:**
- Acute Results of a 52-Patient Cohort at a Single Center with the DABRA Atherectomy System
- DABRA System Study - A Prospective, Multi Center Pilot Study Evaluating Plaque
- Photoablation Using the RA-308 Excimer Laser in Subjects With Symptomatic Intrainguinal Lower Extremity Vascular Disease Evaluating Plaque Photoablation Using an Excimer Laser in Patients With Lower Extremity Vascular Disease

**Commercial Approval:**
- on January 13, 2016, Ra Medical Systems, Inc. received Food and Drug Administration (FDA) approval for patient testing of its novel arterial laser and catheter, the DABRA system (Destruction of Arteriosclerotic Blockages by Laser Radiation Ablation). A preliminary study conducted outside the United States has yielded outstanding results. The DABRA system builds on knowledge gained from the Company's decade of experience with its FDA cleared PHAROS excimer laser system for dermatological diseases.

**Development Status - Commercial Events:**
- On June 21, 2019 Ra Medical Systems, Inc. (NYSE: RMED) announced two live cases and an expert panel presentation of clinical outcomes utilizing DABRA for the treatment of peripheral artery disease (PAD) to occur at the C3 Global Summit.
- On May 20, 2019 Ra Medical Systems, Inc. announced that Dr. Mohammad Ansari will present DABRA as a treatment for critical limb ischemia (CLI) during a scientific case review May 21 at the SCAI annual meeting in Las Vegas.
- On April 11, 2019 Ra Medical Systems Inc today announced the schedule of key DABRA Excimer Laser Atherectomy events at the upcoming Charing Cross International Symposium in London April 16–18. These events include case and podium presentations and hands-on workshops with Charles Bailey, MD, interventional cardiologist at Heart Endovascular and Rhythm of Texas in San Antonio, USA, and Max Amor, MD, interventional cardiologist at Clinique Louis Pasteur in Nancy, France.
- On March 07, 2019 Ra Medical Systems Inc announced study results from Athar Ansari, MD, Director of the California Heart & Vascular Clinic, who stated, “DABRA is fundamentally changing the way I practice medicine.” Dr. Ansari’s study demonstrated a 94% success rate treating peripheral artery
disease (PAD) by ablating arterial blockages. He presented his findings at this year's Joint Interventional Meeting in Milan, Italy.

**Development Status - Clinical Trials:**

On June 19, 2019 Ra Medical Systems, Inc. is conducting a study to demonstrate the DABRA Excimer Laser System delivers effective, long-lasting results and a low reintervention rate for patients with peripheral artery disease (PAD). The study will gather data two years post-treatment in up to 2,500 patients.

On May 30, 2019 Ra Medical Systems, Inc. (NYSE: RMED) Elias Kassab, MD, presented his successful experience using the DABRA laser system. “We have found that DABRA is successful in treating challenging lesions including long and severely calcified lesions, both above and below the knee.” The presentation was delivered on Wednesday, May 29, 2019, at the annual New Cardiovascular Horizons (NCVH) conference in New Orleans.

**Sources:**


**June 19, 2019** --- "Development Status - Clinical Trials" - added that Ra Medical Systems Inc is conducting a study to demonstrate the DABRA delivers effective, long lasting results --- "Source" <https://ir.ramed.com/press-releases/detail/38/ra-medical-clinical-study-aims-to-show-dabra-keeps-arteries>


Last Update: July 9, 2019